Cointime update: Zai Lab announced positive preliminary first-in-human results from the single-ascending-dose portion of the global Phase 1/1b study of ZL-1503, its self-developed long-acting IL-13/IL-31 receptor alpha bispecific antibody. The results are to be presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting. The company said the data may support reduced dosing intervals.
Zai Lab Reports Positive First-in-Human Data for ZL-1503 in Atopic Dermatitis
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
9m ago
THORWallet integrates Hyperliquid for in-wallet spot and perpetual trading
36m ago
CoinShares Q3 AUM Rebounds to $7.4B, Turns Profit; Board Approves Up to $40M Buyback
54m ago
Listed Bitcoin Miners Sell Nearly Half Their BTC Reserves to Fund AI Data Centers
58m ago
Bitwise Files S-1 for Spot Zcash ETF on Texas Stock Exchange
2h ago
Etherscan Flags Unauthorized Access Attempt on Support Ticket System
2h ago
Goldman Sachs’ Ethereum ETF Holdings Rise to $1.22B in Q3, ETHA Stake Up 352%